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Abstract:  Probiotics are live bacteria that could exert health beneficial effects upon 
consumption. In additional to their conventional use as gut modulators, probiotics are 
investigated for their role to prevent cancer. In-vivo and molecular studies have 
demonstrated encouraging outcomes, mainly attributed to its antimicrobial effects against 
carcinogen-producing microorganisms, antimutagenic properties, and alteration of the tumor 
differentiation processes. Prebiotics are indigestible food components that could promote 
the growth of beneficial bacteria including probiotics. Present studies have suggested that 
prebiotics also possess protective effect against colon carcinogenesis, mainly attributed to 
the production of short chain fatty acids upon its fermentation by gut microflora, and 
alteration of gene-expressions in tumor cells. Synbiotic (combination of probiotic and 
prebiotic) has been found to exert a synergistic effect in improving colon carcinogenesis 
compared to when both were used individually. This paper highlights the colon cancer 
preventive effects by probiotics, prebiotics and synbiotics. In addition, the controversial 
outcomes on the insignificant effect of these food adjuncts will be discussed. 
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1. Introduction  
Probiotics are defined as ‘live microorganisms which when administered in adequate amounts 
confer a health benefit on the host’ [1]. Certain strain of bacteria haven been discovered over the years 
to have probiotic properties, mainly consisting of lactic acid producing bacteria (lactobacilli, 
streptococci, enterococci, lactococci, bifidobacteria), Bacillus and fungi such as Saccharomyces and Int. J. Mol. Sci. 2008, 9  855
 
 
Aspergillus. Probiotics is well-known for its roles in modulating a healthier gut. Now, probiotics are 
found to exert other health advantages such as improving lactose intolerance, increasing humoral 
immune responses, biotransformation of isoflavone phytoestrogen to improve post-menopausal 
symptoms, bioconversion of bioactive peptides for antihypertension, and reducing serum cholesterol 
level [2]. A prebiotic is a non-digestible food ingredient that beneficially affects the host by selectively 
stimulating growth, activity, or both of one or a limited number of bacterial species already resident in 
the colon [3]. To exhibit such effects, a prebiotic must neither be hydrolysed nor absorbed in the upper 
part of the gastrointestinal tract, and must be selective for one or a limited number of potentially 
beneficial bacteria such as probiotics that are residing in the colon [4]. Another possibility of gut 
microflora management is the use of synbiotics, where probiotics and prebiotics are used in 
combination. 
Colorectal cancer represents a major public health problem
 accounting for over 1 million cases and 
about
 half a million deaths worldwide [5]. Survival from colon cancer at 5 years has been found to 
vary demographically and estimated to be 65% in North America, 54% in Western Europe, 34% in 
Eastern
 Europe, and 30% in India
 [6]. Although chemotherapy and radiotherapy have been applied as 
the surgical adjuvant treatments of colon cancer, they vary in success rates for local
 recurrence, 
disease-free survival, and overall survival [7]. In addition, these treatments may present some side 
effects such as an increased risk for infections, hair loss, fatigue, lip sores, nausea, vomiting, diarrhea, 
and bloody stools. Diet interventions and natural bioactive supplements have now been extensively 
studied to reduce the risks of colon cancer, as a cause of prevention instead of cure. Postulated 
mechanisms include reduction in the activity of several cancer causing bacteria, desmutagenic and 
anticarcinogenic properties [4,5]. Prebiotics, being indigestible, have been associated with improved 
bowel functions and metabolisms of the distal colon, including a reduced risk of colon cancer. Lower 
tumor numbers have been observed in rats treated with carcinogens when they were fed cereal bran 
[8]. One of the main postulated mechanisms is the production of short chain fatty acids especially 
butyrate via the fermentation of prebiotics by gut flora. In addition, synbiotic products have also been 
found to exert increased benefits compared to the administration of either probiotic or prebiotic alone.  
This present review highlights some of the roles of probiotics, prebiotics and synbiotics on the 
prevention of colon cancer. Hypotheses and in-vivo evidence will be provided and some controversial 
results will be discussed. 
2. Protective Roles of Probiotics on Colon Cancer 
Early studies had indicated that the general population of intestinal bacteria is associated with 
initiation of colon cancer via the production of carcinogens, co-carcinogens, or pro-carcinogens [9]. A 
previous study has reported that only 20% of germ-free animals were shown to develop chemically 
induced colon tumors, as compared with 93% of their counterparts with a normal flora [10]. Using 
azoxymethane-induced aberrant crypt foci in rats, Reddy et al. [11] found that a stimulated growth of 
bifidobacteria in the colon could lead to the inhibition of colon carcinogenesis. The authors suggested 
that the inhibition of aberrant crypt foci and crypt multiplicity was attributed to the pH-lowering effect 
of bifidobacteria in the colon, which subsequently inhibited the growth of E. coli and clostridia. A Int. J. Mol. Sci. 2008, 9  856
 
 
decrease in growth of such pathogenic microorganisms may also produce the modulation of bacterial 
enzymes such as beta-glucuronidase that can convert pro-carcinogens to proximate carcinogens [12]. 
Such anticarcinogenic properties have also been studied at a molecular level. There are fifty-seven 
cytochrome P450 encoded in the human genome, mainly catalyzing the metabolism of steroids, bile 
acids, eicosanoids, drugs and xenobiotic chemicals [13]. However, some of the P450s are also active 
carcinogens. Past epidemiological researches have shown increased risk
 of colon cancer in individuals 
with high P4501A2 activity. The metabolic activation of food-borne heterocyclic amines to colon
 
carcinogens in humans is hypothesized to occur via N-oxidation followed by
 O-acetylation to form the 
N-acetoxy arylamine that binds to DNA to give
 carcinogen-DNA adducts. These steps are catalyzed by 
hepatic cytochrome
  P4501A2 and acetyltransferase-2 (NAT-2), respectively [14]. It has been 
postulated that probiotics such as Bifidobacterium could lower the risks of colon cancer, by producing 
metabolites that could affect the mixed-function of P450s and subsequently affect the conversion of 
azoxymethane from proximate to ultimate carcinogen [15]. These had led to the suggestion that 
probiotic could suppress colon cancer. 
In-depth investigations have also showed that cultured milk possess desmutagenicity and this 
activity increase with increasing numbers of viable cells, indicating that probiotic play an important 
role in the inhibition of mutagenicity [16]. Thyagaraja and Hosono [17] found that probiotic isolated 
from “idly”, a traditional cereal pulse product of India could exert desmutagenicity on various spice 
mutagens, heterocyclic amines and aflatoxins. Subsequent studies on the desmutagenicity properties of 
probiotic suggested that the desmutagenic substances may reside in the cellular envelope of the 
bacterial cell wall [10]. Cell wall preparation of B. infantis was found to inhibit tumor activity in 
mouse peritoneal cells in-vitro [18], while cell wall preparation of heat-killed L. casei (LC9018) was 
found to induce immunity against tumor induction in a randomized, controlled and comparative study 
involving 223 patients with stage III cervical cancer. The antitumor effects were found to be due to the 
activation of macrophage by LC9018 [19]. Also, mutagens were suggested to be bound to the cell wall 
of probiotics. This has been supported by previous studies that have found binding properties by 
fractions of the cell wall skeleton of probiotics on mutagens [20] and the binding of heterocyclic 
amines by intestinal probiotics [21]. In addition, whole cells of bifidobacteria have also been found to 
bind with the ultimate carcinogen methylazoxymethanol [12] and mutagen-carcinogen 3-amino-1,4-
dimethyl-5H-pyrido[4,3-b]indole [22], thus physically removing it via feces and subsequently 
minimizing its absorption into the intestinal lumen.  
Other studies have postulated that probiotics possess colon cancer protective effects by altering the 
differentiation process of tumor cells. Using a cultured human colon cancer cell line (HT-29), 
Baricault et al. [23] studied the effect of fermented
 milks on colon cancer cell growth. Milks were 
fermented with individual strains of Lactobacillus helveticus, Bifidobacterium, L. acidophilus
 or a mix 
of  Streptococcus thermophilus and L. delbrueckii subsp.  bulgaricus. The HT-29 cells were 
subsequently added into the fermented milk, and the authors found that 10-50% of the HT-29 cells 
showed a decrease in growth. Further analyses revealed that the specific activities of specific marker 
for HT-29 cell differentiation such as the dipeptidyl peptides were increased. The authors suggested 
that the tumor cells entered a differentiation process leading to lower growths.  
Using male weanling F344 rats, Singh et al. [10] evaluated the effect of B. longum on colon 
carcinogenesis. Results from their 40-week study demonstrated that dietary administration of Int. J. Mol. Sci. 2008, 9  857
 
 
lyophilized cultures of B. longum resulted in a suppression of colon tumor incidence and tumor 
multiplicity and also reduced tumor volume. Analyses on intermediate biomarkers revealed that 
ingestion of B. longum inhibited azoxymethane-induced cell proliferation via a reduction in ornithine 
decarboxylase (ODC) activity. ODC is involved in the biosynthesis of polyamines that causes cell 
proliferation, differentiation and macromolecular synthesis. Increased ODC activity has been 
associated with increasing colon adenomas and carcinomas which indicate a hyperproliferative state of 
the colonic mucosa [24]. In addition, Singh et al. [10] also found that the strong antitumor activities 
and the reduction in the outcome of tumor were attributed to a reduced expression of ras-p21 
oncoprotein when rats were fed B. longum. Activation of ras proto-oncogens could induce a malignant 
phenotype in colonic cells [25]. The malignant potential of ras genes has been associated with a 
mutational activation in codons 12,13 or 16 [26]. Such a mutation is most observed in the human colon 
tumors, in aberrant crypt foci, colon adenomas and carcinomas [10]. 
3. Roles of Prebiotics and Synbiotics 
Most of the protective effects of prebiotics on colon cancer have emphasized on the oligofructose-
based prebiotics such as fructooligosaccharides and inulin. In one of the animal trial conducted (trial of 
31 weeks), Femia et al. [27] reported that the protective effect of probiotics on azoxymethane-induced 
carcinogenesis was less compared to the effects of prebiotics (oligofructose-inulin). Although the 
authors found that probiotics could reduce malignant tumors in the colon of rats, their effect was 
insignificant statistically, while colonic proliferation was lower when rats were fed the prebiotics. The 
authors subsequently conducted further studies on the expression of genes codifying
 enzymes involved 
in colon carcinogenesis processes. Glutathione S-transferase
 and GST placental enzyme pi type were 
found to be expressed lower when rats were fed the prebiotic individually and when fed in 
combination with Lactobacillus  rhamnosus GG and Bifidobacterium
 lactis Bb12. In addition, the 
inducible nitric oxide synthase, found to play
 an important role in colon tumor growth and progression 
[28], was also depressed
 in the tumors from rats in the prebiotic group. The authors also evaluated the 
levels of cyclooxygenase-2, an enzyme found to be up-regulated in cancers [29], and cyclooxygenase-
2 inhibitors which are often associated with chemopreventive
 activities. Cycloxygenase-2
 expression 
was found to be increased in the tumours of the control rats but
 not in those fed prebiotics. Although 
the exact mechanisms remain unknown, Femia et al. [27] postulated that prebiotic reduced 
carcinogenesis via modification of gene-expressions. 
The fermentation of prebiotics in the colon often generates short chain fatty acids (SCFA). 
Considering that butyrate is not a common end-product from the fermentation of lactobacilli and 
bifidobacteria, its production would originate from the fermentation by other intestinal flora. It has 
been found that butyrate is produced in the colon at varying concentrations depending on the type of 
prebiotics [30]. Although the production of butyrate is approximately 5% of total SCFA, it is of 
particular interest because butyrate has been found to induce differentiation of phenotype including 
colorectal tumor cells [31]. The reduction of colonic cell proliferation and induction of differentiation 
in colonic epithelial cells have now led to increased clinical trials of butyrate in the treatment of 
ulcerative colitis [11]. In addition, sodium butyrate was revealed as a powerful inhibitor of growth and 
inducer of phenotype differentiation and apoptosis and is considered to exert beneficial effects in Int. J. Mol. Sci. 2008, 9  858
 
 
reducing risk factors involved in the etiology of colon cancer and adenoma development [32]. 
Treptow-van Lishault et al. [33] found that the fermentation of gut bacteria on a retrograded, high 
amylose starch had produced butyrate that may increase the detoxification of
  both electrophilic 
products and compounds associated with oxidative
 stress. The enzyme induction by butyrate, or by the 
microflora
 and increased activity by prebiotics, may be an important mechanism
 of protection against 
carcinogen-enhanced colon cancer [34]. 
The combination of suitable prebiotics with probiotic/s has been found to enhance the survival and 
activity of the organism, both in in-vitro and in-vivo experiments, for example a fructooligosaccharide 
in conjunction with a Bifidobacterium strain or lactitol in conjunction with Lactobacillus [3]. The 
combination of prebiotic and probiotic has synergistic effects because in addition to promoting growth 
of existing strains of beneficial bacteria in the colon, synbiotics also act to improve the survival, 
implantation and growth of newly added probiotic strains. The combination of Bifidobacterium and 
oligofructose synergistically retarded colon carcinogenesis in rats compared to when both were given 
individually [35]. In a randomized, double-blind and placebo-controlled
  trial, Rafter et al. [36] 
evaluated the effect of synbiotic on reducing cancer risk factors in 37 colon cancer patients
 and 43 
polypectomized patients. The synbiotic contained Lactobacillus rhamnosus GG and Bifidobacterium
 
lactis Bb12 as the probiotics and oligofructose-enriched
 inulin as the prebiotic. The authors found that 
certain colorectal cancer intermediate biomarkers can be altered
 via synbiotic intervention, where 
colorectal proliferation and the capacity of fecal water
 to induce necrosis in colonic cells were reduced. 
In addition, polypectomized patients showed improved epithelial barrier
  functions. The authors 
conducted genotoxicity assays using the colonic biopsy samples, and found that the exposure to 
genotoxins
 in polypectomized patients decreased at the end of the intervention period. Although the 
exact mechanisms of these remain unknown, the authors postulated that the synbiotic intervention had 
contributed to the alterations in the composition of the colonic bacterial ecosystem,
 and subsequently 
the metabolic activity
 of the colon. 
4. Controversial Findings 
Despite all the claimed colon cancer protective effects, not all investigations support this outcome, 
where in-vivo trials have given inconsistent data. Such contradictory results obtained may be related to 
the complexity of carcinogenesis, experimental design, complications in obtaining the appropriate 
sample sizes, variation in the type of probiotic strains and variations in the tumor stages of subjects. In 
addition, the desired protective effects have also been found to depend on the dose of probiotics 
administered. A protective effect of L.
 casei against carcinogen-induced lesions in colon cells of rats 
were observed, when the probiotics were administered at a level of 1 x 10
10 bacteria in 10 mL NaCl/kg 
body weight. Similarly, a single dose of living
 L. acidophilus, L. gasseri, L.
 confusus, Streptococcus 
thermophilus, B. breve,
 and B. longum was found to prevent MNNG-induced DNA damage
 in the 
colon. However, a reduced bacterial
 dose of 50% or 90% had resulted in the loss of the carcinogen 
protection effects [37]. This may be attributed to the probiotic dose-dependent stimulation of gut 
immune cells to release inflammatory and regulatory cytokines such as gamma interferon, interleukin-
12 (IL-12), IL-14 and IL -10 [38]. Int. J. Mol. Sci. 2008, 9  859
 
 
Moore and Moore [39] evaluated the relationships between intestinal flora of different nationalities 
and colon cancer. Subjects from Japan (n=22) and South Africa (n=16) were grouped as low-risk 
populations due to their minimal daily intake of red meat, while the US Caucasians (n=17) were 
grouped as a high-risk population. The authors reported that B. longum and B. angulatum were 
positively associated with a high risk of colon cancer, where their populations were found to increase 
with increased risk of colon cancer. In addition, increased numbers of Bifidobacterium was detected in 
the flora of the high-risk populations, a contrary to some suggestions by commercial companies that 
ingestion of Bifidobacterium might offer increased protection against colon cancer. Considering that 
the high-risk subjects were determined by their diets, results from this study indicated that the 
population of bifidobacteria is diet-related, where they favourably grow in the presence of red-meat. 
Such a correlation is not new, as a previous study also reported that the population of B. infantis was 
higher in subjects consuming a Western diet than those on a native Japanese diet [40]. This could be a 
matter of concern, because bifidobacteria are often taken as a probiotic supplement with 
anticarcinogenic effects, and should not exhibit colon cancer potentials. More studies are needed for 
in-depth understanding on this matter, to ensure that the detrimental effects of bifidobacteria do not 
outweigh their widely claimed-benefits.  
Another study on inulin also reported such controversial findings. It has been highly publicized that 
diets high in red meat and low in fiber would increase the risks of colon cancer. Mutanen et al. [41] 
conducted a study to determine whether such a claim would be scientifically sound, by feeding rats a 
high-beef diet with or without oat, rye-wheat bran and inulin. Although the rye-bran group showed 
lowest number of polyps in the distal small intestine, the authors found that the inulin group was close 
to the beef group and was significantly different (P<0.05) from the rye-bran group. In addition, the 
number of animals bearing tumours in the colon and caecum was 89% in the beef group and 100% in 
the inulin group. In order to determine a possible explanation for this, the authors measured mucosal 
levels of a target molecule for APC protein, the β-catenin. A higher concentration of β-catenin has 
been associated with malfunction of the APC protein, where β-catenin could stimulate gene expression 
in the nuclease. Mice fed the inulin diet was found to have the highest level of cytosolic ß-catenin
 in 
additional to the lowest number of adenomas. The authors postulated that the inulin diet promoted the 
formation of intestinal tumors via increasing the level of cytosolic
 ß-catenin. Other contradictory 
results on the use of prebiotics on colon cancer have also been reported over the years and are 
presented in Table 1. 
5. Conclusions 
The use of probiotics and prebiotics to prevent colon cancer has gained much attention due to 
positive outcomes from in-vivo and molecular studies. Various mechanisms have been proposed 
including its anticarcinogenic effects, antimutagenic properties, modification of differentiation 
processes in tumor cells, production of short chain fatty acids, and alteration of tumor gene-
expressions. Despite all the positive findings, other researches have also reported insignificant colon 
cancer protective effects. However, the increased interest in these areas demonstrated the need for 
further evaluation to better understand the exact mechanisms involved, and to generate uncontroversial 
experimental evidence. Int. J. Mol. Sci. 2008, 9  860
 
 





No. of subjects 
Subject types 
Age (years) 
Study design  Results and conclusions  References 
Wheat bran  
 
High amount: 13.5 
g/day or Low 
amount: 2.0 g/day 
 
36 months 





removed within 3 
mths  
40-80 years old 
Randomized  Dietary supplement of wheat-bran 
fiber did not protect against 
recurrent colorectal adenomas. At 
least 1 adenoma detected in 47.0% 








16.4 g fiber/day 
 
2 weeks 






subjects (26 male 




51-61 years old 
Randomized  Colonic biopsies taken before and 
after the intervention showed no 
difference in the index of thymidine 
colonic-crypt-cell labeling, 
thymidine-labeling pattern, or 
nuclear aberrations between oat and 
wheat brans. Difference between 
polyp and non-polyp subjects was 
insignificant. 
[43] 
Low fat (20% of total 
calories), high-fiber 
(18 g dietary fiber/ 
1000kCal/day) and 
3.5 servings of fruits 










removed within 6 
mths 
≥ 35 years old 
Randomized  39.7% from the treatment group 
and 39.5% from the control group 
experienced at least one recurrent 
adenoma. Adopting a diet that is 
low in fat and high in fiber, fruits, 
and vegetables did not influence the 
risk of recurrence of colorectal 
adenomas. 
[44] 
Ispaghula husk (given 
as 3.5 of orange 
flavored effervescent 




665 patients with 
≥ 2 adenomas or 
1 adenoma of > 
5mm in diameter 





Patients in the fiber group had a 
45% increase in 
recurrent adenomas relative to the 
placebo group after 3 
years {p = 0.04}. Supplementation 
with ispa- 
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